Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics (populations A and B)

From: New method for the mathematical derivation of the ventilatory anaerobic threshold: a retrospective study

  Population A healthy (n = 67) Population A with CV risks (n = 20) Population A cardiac (n = 41) Population B cardiac (n = 163)
Age, y 37 ± 20* 59 ± 11 67 ± 9 63 ± 10
Sex (male/female) 48/19 20/0 26/15 141/22
Body weight, kg 62 ± 11* 72 ± 7 59 ± 9 66.1 ± 10.9
Body mass index, kg/m2 22.1 ± 3.0* 25.8 ± 2.8 23.3 ± 3.1 24.7 ± 3.2
Heart disease etiology: ischemic (%) NA NA 76 84
Weber class: A/B/C/D NA NA   
 Using VO2peak (n)    7/12/20/2 NA
 Using VAT (n)    1/16/18/6 11/40/66/29
Medications (n) NA    
 ACE or ARB   9 16 91
 Diuretic   2 7 51
 Beta-blocker   0 17 72
 Inotropics   0 0 4
 Ca channel blocker   17 7 35
 Anti-lipidemic   3 16 85
 Anti-diabetic   2 4 42
  1. *p-Value was significant at least at < 0.05 by 1-way analysis of variance
  2. Weber-Janicki functional classification: Using VO2peak, based on VO2peak; Using VAT, based on the ventilatory anaerobic threshold
  3. CV cardiovascular, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, Ca calcium